ELIMINATE

Main information

  • Trade name:
  • ELIMINATE 10/10 TAB
  • Dosage:
  • 125/250;MG
  • Pharmaceutical form:
  • TAB
  • Composition:
  • 10/10
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • ELIMINATE 10/10 TAB
    India
  • Language:
  • English

Other information

Status

  • Source:
  • Central Drugs Standard Control Organization
  • Last update:
  • 09-08-2016

17-10-2018

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The duration of the vaccination campaign sufficient to eliminate lumpy skin disease (LSD) mainly depends on the vaccination effectiveness and coverage achieved. By using a spread epidemiological model, assuming a vaccination effectiveness of 65%, with 50% and 90% coverage, 3 and 4 years campaigns, respectively, are needed to eliminate LSD. When vaccination effectiveness is 80% to 95%, 2 years of vaccination at coverage of 90% is sufficient to eliminate LSD vir...

Europe - EFSA - European Food Safety Authority Publications

14-9-2018

FDA Releases Five-Year Plan for Supporting Antimicrobial Stewardship in Veterinary Settings

FDA Releases Five-Year Plan for Supporting Antimicrobial Stewardship in Veterinary Settings

CVM’s five-year action plan for supporting antimicrobial stewardship in veterinary settings builds upon the important steps CVM has taken to eliminate production uses of medically important antimicrobials.

FDA - U.S. Food and Drug Administration

4-9-2018

Safer prescription of blood thinning agents

Safer prescription of blood thinning agents

A collaboration between pharmaceutical companies, pharmacies and authorities has eliminated a common cause of dosing errors involving blood thinning agents.

Danish Medicines Agency

19-7-2018

Assessment of the safety of feminine hygiene products

Assessment of the safety of feminine hygiene products

Today ANSES is publishing its health risk assessment on the safety of feminine hygiene products. Chemicals have been identified in these products at very low concentrations not exceeding health thresholds. The expert appraisal did not reveal any risk associated with these substances. Nevertheless, the Agency recommends that manufacturers improve the quality of these products in order to eliminate or minimise the presence of chemicals. ANSES’s expert appraisal also examined the risk of menstrual toxic sho...

France - Agence Nationale du Médicament Vétérinaire

There are no news related to this product.